WO2007074346A3 - Modulation de voies de signalisation - Google Patents

Modulation de voies de signalisation Download PDF

Info

Publication number
WO2007074346A3
WO2007074346A3 PCT/GB2006/050465 GB2006050465W WO2007074346A3 WO 2007074346 A3 WO2007074346 A3 WO 2007074346A3 GB 2006050465 W GB2006050465 W GB 2006050465W WO 2007074346 A3 WO2007074346 A3 WO 2007074346A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
modulation
wnt signalling
system disorders
signalling pathways
Prior art date
Application number
PCT/GB2006/050465
Other languages
English (en)
Other versions
WO2007074346A2 (fr
Inventor
Vahri Beaumont
Helmut Glantschnig
Ignacio Munoz-Sanjuan
Christopher John Swain
Original Assignee
Merck & Co Inc
Merck Sharp & Dohme
Vahri Beaumont
Helmut Glantschnig
Ignacio Munoz-Sanjuan
Christopher John Swain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Merck Sharp & Dohme, Vahri Beaumont, Helmut Glantschnig, Ignacio Munoz-Sanjuan, Christopher John Swain filed Critical Merck & Co Inc
Publication of WO2007074346A2 publication Critical patent/WO2007074346A2/fr
Publication of WO2007074346A3 publication Critical patent/WO2007074346A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation d'un modulateur d'une voie de signalisation Wnt dans la préparation d'un médicament pour le traitement de maladies dégénératives et de troubles dans lesquels la perte synaptique ou la tonalité afférente dans le système nerveux central et périphérique est affectée, tels que la maladie d'Alzheimer et la sclérose latérale amyotrophique (SLA) et des infirmités motrices cérébrales.
PCT/GB2006/050465 2005-12-28 2006-12-19 Modulation de voies de signalisation WO2007074346A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0526515.2 2005-12-28
GBGB0526515.2A GB0526515D0 (en) 2005-12-28 2005-12-28 Modulation of signalling pathways

Publications (2)

Publication Number Publication Date
WO2007074346A2 WO2007074346A2 (fr) 2007-07-05
WO2007074346A3 true WO2007074346A3 (fr) 2007-11-29

Family

ID=35841291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/050465 WO2007074346A2 (fr) 2005-12-28 2006-12-19 Modulation de voies de signalisation

Country Status (2)

Country Link
GB (1) GB0526515D0 (fr)
WO (1) WO2007074346A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110243959A1 (en) * 2008-11-04 2011-10-06 Pico Caroni Modulating neuronal plasticity and treatment of neuronal loss by modulationg wnt7a or wnt7b modulation
US11504397B2 (en) * 2019-02-07 2022-11-22 University Of South Carolina Methods and compositions for modulating the WNT-signaling pathway as treatments for inflammatory diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6456614A (en) * 1987-08-27 1989-03-03 Ono Pharmaceutical Co Maillard reaction inhibitor
EP0797098A2 (fr) * 1996-03-22 1997-09-24 Roche Diagnostics GmbH Procédé pour stabiliser bilirubine dans des sérums de contrÔle et des calibrateurs
FR2832406A1 (fr) * 2001-11-21 2003-05-23 Pernod Ricard 7-nitroindazole 3 substitues, procede de preparation et utilisation therapeutique notamment pour le traitement de la dependance alcoolique
WO2003055490A1 (fr) * 2001-12-24 2003-07-10 Merck Patent Gmbh 4-aryl-chinazolines et utilisation en tant qu'inhibiteurs de nhe-3
WO2004113513A2 (fr) * 2003-06-25 2004-12-29 Ottawa Health Research Institute Procedes et compositions pour moduler la croissance et la differentiation des cellules souches

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6456614A (en) * 1987-08-27 1989-03-03 Ono Pharmaceutical Co Maillard reaction inhibitor
EP0797098A2 (fr) * 1996-03-22 1997-09-24 Roche Diagnostics GmbH Procédé pour stabiliser bilirubine dans des sérums de contrÔle et des calibrateurs
FR2832406A1 (fr) * 2001-11-21 2003-05-23 Pernod Ricard 7-nitroindazole 3 substitues, procede de preparation et utilisation therapeutique notamment pour le traitement de la dependance alcoolique
WO2003055490A1 (fr) * 2001-12-24 2003-07-10 Merck Patent Gmbh 4-aryl-chinazolines et utilisation en tant qu'inhibiteurs de nhe-3
WO2004113513A2 (fr) * 2003-06-25 2004-12-29 Ottawa Health Research Institute Procedes et compositions pour moduler la croissance et la differentiation des cellules souches

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198915, Derwent World Patents Index; AN 1989-110597, XP002438525 *
FUJIKAWA, FUKUJIRO ET AL: "Chemotherapeutic agents against Mycobacterium tuberculosis. XXVI. Synthesis and antituberculous activity of phenylthiourea, p-ethoxyphenylthiourea, and 3-bromo-4-ethoxyphenylthiourea derivatives", YAKUGAKU ZASSHI , 91(2), 159-65 CODEN: YKKZAJ; ISSN: 0031-6903, 1971, XP008080259 *
NAGARAJAN, K. ET AL: "Anticonvulsant 1-arylsemicarbazides and thioureas", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY , 24B(9), 934-9 CODEN: IJSBDB; ISSN: 0376-4699, 1985, XP008080261 *
TOKU, HIROSHIGE ET AL: "Synthesis and antimicrobial activities of thiosemicarbazides", BOKIN BOBAI , 12(1), 9-19 CODEN: BOBODP; ISSN: 0385-5201, 1984, XP008080260 *

Also Published As

Publication number Publication date
GB0526515D0 (en) 2006-02-08
WO2007074346A2 (fr) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2004037204A3 (fr) Methodes et composes de perturbation de la signalisation cd40r/cd40l dans le traitement de la maladie d&#39;alzheimer
EP2453024A3 (fr) Gènes et voies exprimés différemment dans le trouble bipolaire et/ou le trouble dépressif majeur
WO2007061750A3 (fr) Cellules stromales derivees de tissus adipeux pour le traitement de troubles neurologiques
WO2008011476A3 (fr) Compositions et procédés destinés à moduler l&#39;activité de la sirtuine
MX2011002705A (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
WO2007127505A3 (fr) Composés chimiques
WO2006071778A3 (fr) Traitement de la maladie de parkinson et de troubles associes au moyen de cellules derivees postnatales
WO2007071055A8 (fr) Compositions et procedes de modulation de canaux ioniques commandes par porte
EP3011970A3 (fr) Modulation de la dégénérescence axonale
WO2007127475A3 (fr) Compositions et traitements contre des maladies démyélinisantes et des troubles de type douleur
WO2009065596A3 (fr) Utilisation d&#39;inhibiteurs de mnk pour le traitement de la maladie d&#39;alzheimer
WO2005081619A3 (fr) Composes et procedes pour accroitre la neurogenese
WO2007058805A3 (fr) Compositions et procedes destines au traitement des troubles du snc
HK1087351A1 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
WO2002036829A3 (fr) Procedes de diagnostic de prevention et de traitement de troubles neurologiques et de lesions neuronales
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
WO2007092165A3 (fr) Compositions et procedes destines a accroitre la plasticite et la regeneration neuronales
WO2004110359A3 (fr) Proteines de fusion destinees au traitement du systeme nerveux central
ATE526981T1 (de) Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
WO2007074346A3 (fr) Modulation de voies de signalisation
NO20050385L (no) Anvendelse av PP2A-fosfatasemodulatorer i behandlingen av mentale lidelser
WO2006101910A3 (fr) Composes peptidiques et procedes d&#39;utilisation de composes peptidiques dans le traitement d&#39;etats pathologiques affectant les systemes cardiaque, pulmonaire et nerveux
WO2005061002A3 (fr) Composition et procedes pour la modulation de l&#39;activite du systeme nerveux central
WO2004047727A3 (fr) Compositions et procedes pour diagnostiquer et traiter des troubles de l&#39;humeur
WO2004096157A3 (fr) Traitement de maladies a depot d&#39;iga1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06820690

Country of ref document: EP

Kind code of ref document: A2